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Introduction
Wnt proteins derived from the Drosophila Wingless (Wg) and the 
mouse Int-1 genes are secreted cysteine-rich glycosylated proteins 
that oversee multiple cellular functions such as stem cell devel-
opment, vascular regeneration, and maturation of the nervous 
system.1-8 Wnt proteins also are intimately tied to disorders that 
involve metabolic homeostasis and cardiovascular disease.9-11 For 
example, abnormalities in Wnt pathways, such as with transcrip-
tion factor 7-like 2 gene, can have an increased risk for type 2 
diabetes12-14 and be associated with the development of obesity.15 
In addition, patients with coronary artery disease and the com-
bined metabolic syndrome with hypertension, hyperlipidemia, 
and  diabetes  have  shown  impaired  Wnt  signaling  through  a   
missense mutation in LRP-6.16 Wnt family members also may 
provide cellular protection during periods of elevated glucose. 
Although essential for the development of the nervous system, Wnt1 also has been associated with neurodegenerative 
disease and cognitive loss during periods of oxidative stress. here we show that endogenous expression of Wnt1 is 
suppressed during oxidative stress in both in vitro and in vivo experimental models. Loss of endogenous Wnt1 signaling 
directly correlates with neuronal demise and increased functional deficit, illustrating that endogenous neuronal Wnt1 
offers a vital level of intrinsic cellular protection against oxidative stress. Furthermore, transient overexpression of Wnt1 
or application of exogenous Wnt1 recombinant protein is necessary to preserve neurological function and rescue 
neurons from apoptotic membrane phosphatidylserine externalization and genomic DNA degradation, since blockade 
of Wnt1 signaling with a Wnt1 antibody or dickkopf related protein 1 abrogates neuronal protection by Wnt1. Wnt1 
ultimately relies upon the activation of Akt1, the modulation of mitochondrial membrane permeability, and the release 
of cytochrome c to control the apoptotic cascade, since inhibition of Wnt1 signaling, the phosphatidylinositol 3-kinase 
pathway, or Akt1 activity abrogates the ability of Wnt1 to block these apoptotic components. Our work identifies Wnt1 
and its downstream signaling as cellular targets with high clinical potential for novel treatment strategies for multiple 
disorders precipitated by oxidative stress.
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Wnt can promote increased insulin sensitivity17 and protect glom-
erular mesangial cells from elevated glucose induced apoptosis.18 
For the Wnt1 family member, studies demonstrate that Wnt1 
works in conjunction with the cytokine erythropoietin to impart 
cellular protection during elevated glucose exposure.19-21
The Wnt pathway also plays a role in nervous system dis-
orders  and  can  be  upregulated  in  models  of  frontotemporal   
dementia.22 It is conceivable that the increased expression of Wnt 
may improve memory function since agents such as lithium chlo-
ride that enhance Wnt signaling activity have shown to be ben-
eficial for cognition.23 Genetic analysis also suggests that LRP-6 
variants of the Wnt pathway may be associated with late onset 
Alzheimer disease24 and that upregulation of the Wnt pathway, 
such as with agents as cannabidiol, may provide alternative treat-
ments for Alzheimer disease.25 In cell culture models of Alzheimer 
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through  increased  Wnt  signaling  and  β-catenin  activity.26  In 
particular, Wnt pathways controlled by Wnt1 are of considerable 
interest since Wnt1 appears critical for neuronal protection dur-
ing β-amyloid exposure against apoptotic neuronal injury and 
microglial activation.27
Here we show that endogenous and exogenous Wnt1 is vital 
for the protection of primary neurons during oxidative stress in 
both in vitro and in vivo experimental models. In primary neu-
rons  with  oxygen-glucose  deprivation  (OGD),  suppression  of 
endogenous Wnt1 correlates with neuronal cell demise. Transient 
overexpression of Wnt1 or application of exogenous recombinant 
Wnt1 is crucial for the prevention of early apoptotic membrane 
PS externalization and subsequent DNA degradation, since loss of 
Wnt1 signaling through blockade by Wnt1 antibody (Wnt1Ab) 
or the recombinant Wnt antagonist dickkopf related protein 1 
(DKK-1) leads to the loss of neuronal protection. Furthermore, 
Wnt1 reduces cerebral infarction and markedly improves neuro-
logical recovery during reversible middle cerebral artery occlusion 
(MCAO) in rats. Yet, blockade of Wnt1 signaling during MCAO 
significantly enhances cerebral infarction and neurological defi-
cit, illustrating that endogenous neuronal Wnt1 also provides 
an important intrinsic level of neuroprotection during oxidative 
stress. Control of neuronal apoptotic injury by Wnt1 ultimately 
relies upon the activation of Akt1, the modulation of mitochon-
drial  membrane  permeability,  and  the  release  of  cytochrome 
c, since inhibition of Wnt1 signaling, the phosphatidylinositol 
3-kinase (PI 3-K) pathway, or Akt1 activity abrogates the ability 
of Wnt1 to control these apoptotic pathways. Our work iden-
tifies Wnt1 and its downstream signaling as possible pathways   
with high clinical potential for the targeting of multiple disorders 
precipitated by oxidative stress.
Results
Oxygen-glucose deprivation (OGD) results in cellular injury 
and reduced Wnt1 expression in neurons. We initially investi-
gated neuronal survival after exposure to OGD at various peri-
ods of exposure of 1 hour, 2 hours, 3 hours and 4 hours. Cell 
survival was assessed with trypan blue exclusion 24 hours after 
OGD exposure. In Figure 1A, neuronal survival was significantly 
reduced over progressive times following OGD application to 73 
± 3% (1 hour), 51 ± 4% (2 hours), 32 ± 3% (3 hours), and 20 
± 3% (4 hours) when compared with untreated control cultures 
(86 ± 3%, p < 0.01). Since OGD exposure for a period of 3 hours 
resulted in survival rate of approximately 30% (a 70% neuronal 
cell loss), this duration of OGD was used for the reminder of the 
experimental paradigms.
We next examined whether OGD alters endogenous Wnt1 
cellular expression. Western blot assay was performed for Wnt1 
protein expression at 1, 6, and 24 hours following exposure 
to OGD that was applied for a 3 hour period. As shown in   
Figure  1B, OGD initially increased the expression of Wnt1 
at 1 and 6 hours when compared to control, but a significant 
decrease in Wnt1 expression in neurons was observed at 24 
hours following OGD exposure that was similar to control lev-
els, suggesting that increases in Wnt1 expression are lost during 
OGD exposure. Quantitative results demonstrate that Wnt1 
expression is significantly increased approximately two-fold at 
1 hour and 2.5-fold at 6 hours following OGD, but is signifi-
cantly decreased to approximately 1.0-fold at 24 hours after 
OGD exposure (Fig. 1B).
Wnt1  protects  against  neuronal  injury  during  OGD.   
In Figure 2A, representative figures show significant trypan blue 
staining in wildtype neurons 24 hours after OGD or with vec-
tor expression during OGD. In contrast, trypan blue uptake is   
significantly  reduced  in  neurons  during  Wnt1  overexpression 
in  the  presence  of  OGD.  On  further  analysis  in  Figure  2A,   
neuronal survival was significantly increased to approximately 
70% during OGD with Wnt1 overexpression but not in wildtype 
cells or during vector expression with OGD.
Wnt1 blocks apoptotic early phosphatidylserine (PS) expo-
sure and subsequent nuclear DNA degradation during OGD.   
Figure 1. OGD leads to progressive injury in neurons and reduces 
endogenous Wnt1 expression over time. In A, primary hippocampal 
neurons were exposed to progressive durations of OGD at 1, 2, 3 and 4 
hours and neuronal survival was determined 24 hours later by trypan 
blue dye exclusion assay. Neuronal survival was decreased to 73 ± 3% (1 
hour), 51 ± 4% (2 hours), 32 ± 3% (3 hours), and 20 ± 3% (4 hours) follow-
ing OGD exposure when compared with untreated control cultures (86 
± 3%, *p < 0.01 vs. Control). each data point represents the mean and 
seM from 6 experiments. In B, neuronal protein extracts (50 μg/lane) 
were immunoblotted with anti-Wnt1 (Wnt1) at 1, 6 and 24 hours follow-
ing OGD exposure. Wnt1 expression is initially elevated at 1 hour and 
6 hours, but then progressively and significantly is reduced at 24 hours 
following OGD exposure (*p < 0.01 vs. control)www.landesbioscience.com  Oxidative Medicine and Cellular Longevity  155
Apoptotic neuronal cell injury consists of both later genomic 
DNA degradation as well as early membrane PS exposure.28,29   
In  addition,  the  externalization  of  membrane  PS  residues  in 
neurons undergoing apoptosis can result in inflammatory cell   
activation  and  identify  these  cells  for  phagocytosis.30,31  We 
therefore examined the ability of Wnt1 to alter genomic DNA 
Figure 2. Transient transfection of Wnt1 increases neuronal survival and prevents genomic DNA degradation and membrane ps externalization. In A, 
overexpression of Wnt1 was performed under the control of a CMV promoter with Wnt1 cDNA and cell survival was determined 24 hours after OGD 
exposure through the trypan blue dye exclusion method. Representative images illustrate decreased trypan blue staining during Wnt1 transient trans-
fection. significant cell injury and trypan blue staining occurs during OGD alone in wildtype cells and during vector transfection. Quantification of 
data demonstrates that OGD significantly decreased percent cell survival when compared to the control cells. In contrast, Wnt1 significantly increased 
cell survival (*p < 0.01 vs. OGD). each data point represents the mean and seM from six experiments. Control = untreated neurons. In B, overexpression 
of Wnt1 was performed under the control of a CMV promoter with Wnt1 cDNA and genomic DNA degradation was determined 24 hours after OGD 
exposure through TUNeL. Representative images illustrate decreased TUNeL staining during Wnt1 transient transfection. significant DNA fragmenta-
tion occurs during OGD alone in wildtype cells and during vector transfection. Quantification of data demonstrates that OGD results in marked DNA 
fragmentation when compared to the control cells. In contrast, Wnt1 significantly prevents DNA fragmentation (*p < 0.01 vs. OGD). each data point 
represents the mean and seM from six experiments. Control = untreated neurons. In C, overexpression of Wnt1 was performed under the control of 
a CMV promoter with Wnt1 cDNA and membrane ps externalization was determined 24 hours after OGD exposure through annexin V phycoerythrin 
(green fluorescence). Representative images illustrate decreased ps staining during Wnt1 transient transfection. significant membrane ps externaliza-
tion occurs during OGD alone in wildtype cells and during vector transfection. Quantification of data demonstrates that OGD results in marked ps ex-
posure when compared to the control cells. In contrast, Wnt1 significantly prevents ps externalization (*p < 0.01 vs. OGD). each data point represents 
the mean and seM from six experiments. Control, untreated neurons.156  Oxidative Medicine and Cellular Longevity  Volume 3 Issue 2
degradation  and  membrane  PS  exposure  in  neurons  during   
OGD exposure. In representative Figures 2B and 2C, untreated 
control  wildtype  neurons  were  without  DNA  fragmentation 
assessed by TUNEL or PS externalization assessed by annexin 
V. In wildtype neurons exposed to OGD or in neurons with 
vector expression during OGD, significant DNA fragmentation 
(TUNEL) and membrane PS exposure (annexin V) occurs 24 
hours after exposure. In contrast, Wnt1 overexpression in the 
presence of OGD significantly prevented DNA fragmentation 
and membrane PS exposure, demonstrating that Wnt1 blocks 
apoptotic programs during OGD.
Wnt1 signaling provides necessary protection against cell 
injury in neurons. In Figure 3A, application of recombinant 
human Wnt1 protein (5-100 ng/ml) in neuronal cultures 1 hour 
prior to OGD exposure significantly increased neuronal cell 
survival. Neuronal survival was significantly reduced to 40 ± 
3% following exposure to OGD when compared with untreated 
control cultures (92 ± 2%, p < 0.01). Yet, application of Wnt1 
prior to OGD significantly increases neuronal cell survival to a 
maximum of 69 ± 3% with a Wnt1 concentration of 100 ng/
ml. As a result, for subsequent experimental protocols, we used 
recombinant Wnt1 protein of 100 ng/ml.
We next examined whether specific antagonism against exog-
enous Wnt1 application with an antibody to Wnt1 (Wnt1Ab) 
could neutralize the protective capacity of Wnt1 during OGD. 
Initially,  we  examined  application  of  the  Wnt1Ab  alone  in 
Figure 3B. Administration of Wnt1Ab (0.01 - 1 μg/ml) alone 
did not significantly alter neuronal survival when compared to 
untreated control cultures (data not shown) or during exposure 
to OGD (Fig. 3B). In the presence of progressive concentrations 
of the Wnt1Ab (0.01 - 1 μg/ml) in combination with recombi-
nant Wnt1 (100 ng/ml) during OGD (Fig. 3C), the protective 
capacity of Wnt1 was significantly reduced and reached a level 
that was similar to neurons exposed to OGD without Wnt1 at 
the Wnt1Ab concentration of 1 μg/ml. In addition, we exam-
ined the application of DKK-1 (0.5 μg/ml), an antagonist of the 
Wnt/β-catenin pathway that binds to LRP5/LRP6 and prevents 
formation of the Wnt/Frizzled/LRP complex,7,32 that has been 
shown to reduce the accumulation of free β-catenin.33 In Figure 
3D, Wnt (100 ng/ml) significantly protected neurons form OGD 
exposure. In contrast, co-administration of Wnt1 (100 ng/ml) 
and DKK-1 (0.5 μg/ml) negated the protective effects of Wnt1, 
illustrating that Wnt1 and its signaling pathways are necessary 
for neuronal protection during OGD.
Figure 3. Wnt1 signaling is necessary for neuronal protection against OGD. In A, increasing concentrations of Wnt1 protein result in significantly 
increased neuronal survival assessed by trypan blue exclusion 24 hours after OGD (*p < 0.01 vs. OGD). In B, increasing concentrations of an antibody to 
Wnt1 (Wnt1Ab) during OGD do not alter neuronal survival assessed by trypan blue exclusion 24 hours after OGD when compared to neurons exposed 
to OGD alone. In C, increasing concentrations of an antibody to Wnt1 (Wnt1Ab) applied with Wnt1 (100 ng/ml) resulted in progressive loss of Wnt1 pro-
tection and increased neuronal cell injury assessed by trypan blue staining 24 hours after OGD (*p < 0.01 vs. OGD). In D, inhibition of Wnt1 signaling 
with DKK-1 (0.5 μg/ml), an antagonist of the Wnt/β-catenin pathway, administered with Wnt1 (100 ng/ml) significantly reduces protection by Wnt1 and 
neuronal cell survival assessed by trypan blue staining 24 hours after OGD (*p < 0.01 vs. OGD; †p < 0.01 vs. Wnt1/OGD). In all cases control = untreated 
neurons. each data point represents the mean and seM from six experiments.www.landesbioscience.com  Oxidative Medicine and Cellular Longevity  157
Wnt1 uses the PI 3-K pathway for neuronal protection 
during OGD. Wnt1 has been shown to employ protein kinase 
B (Akt1) for neuronal protection against amyloid toxicity.27 In 
addition, Akt alone is cytoprotective under a number of injury 
paradigms,  such  as  hyperglycemia,34,35  hypoxia,36  β-amyloid 
(Aβ) toxicity,37 cellular aging,38 neurodegeneration39,40 and oxi-
dative stress.41-43 We therefore examined the ability of Wnt1 to 
alter activity of Akt1 through phosphorylation during OGD 
(Fig. 4A). Western blot assay was performed for phosphorylated 
Akt1 (p-Akt1) and total Akt1 at 6 hours following OGD expo-
sure. For Akt1 phosphorylation, Ser473 was examined since phos-
phorylation of Ser473 is considered to be critical for the complete 
activation of Akt1.44 In Figure 4A, application of Wnt1 (100 ng/
ml) in untreated wildtype neurons or in the presence of OGD 
significantly elevated p-Akt1 expression to a greater extent than 
OGD alone. This increased expression of p-Akt1 was blocked 
by the PI 3-K inhibitor wortmannin (0.5 μM) that forms a cova-
lent link with the lysine residue of PI 3-K45 (Fig. 4A) and by the 
specific Akt1 inhibitor SH-5 (20 μM).46 In Figure 4B, primary 
neurons treated with Wnt1 (100 ng/ml) following OGD expo-
sure increased neuronal survival from 40 ± 3% to 67 ± 3%. 
However, application of wortmannin (0.5 μM) or SH-5 (20 
μM) at concentrations that block activation of Akt1 activation   
(Fig.  4A)  significantly  reduced  protection  by  Wnt1  during 
OGD, suggesting that Wnt1 requires activation of the PI 3-K 
and Akt for neuronal protection during OGD.
Wnt1 through Akt1 is required for neuronal survival dur-
ing apoptotic membrane PS exposure and genomic DNA deg-
radation. In Figure 5A, representative images illustrate that 
OGD alone leads to significant TUNEL staining and mem-
brane PS exposure in neurons. In contrast and similar to our 
studies with Wnt1 overexpression in Figure 2, Wnt1 (100 ng/
ml) administration significantly prevented DNA degradation 
assessed by TUNEL labeling and membrane PS externalization 
assessed by annexin V at 24 hours after OGD exposure (Fig. 
5A and B). Furthermore, during inhibition of Wnt1 activity 
with Wnt1Ab (1 μg/ml) or with application of DKK-1 (0.5 
μg/ml), neuronal protection was lost by Wnt1 with increased 
TUNEL labeling and membrane PS externalization in neurons 
during OGD exposure (Fig. 5A and B). In addition, inhibition 
of Akt1 activity by SH-5 (20 μM) during Wnt1 application 
also result in the loss of Wnt1 cytoprotection, demonstrating 
that the activation of Akt1 is an essential component for Wnt1 
to prevent neuronal genomic DNA degradation and early mem-
brane PS exposure during OGD.
Wnt1 through Akt1 prevents mitochondrial depolariza-
tion and cytochrome c release during OGD. Mitochondrial 
depolarization in neurons was assessed during OGD by the cat-
ionic membrane potential indicator JC-1. In Figures 6A and 
6B, OGD resulted in a significant decrease in the EC mito-
chondrial red/green fluorescence intensity ratio within 3 hours 
(42 ± 10%) when compared to untreated control mitochondria 
(100 ± 16%), demonstrating that OGD results in mitochon-
drial membrane depolarization. Administration of Wnt1 (100 
ng/ml) in the presence of OGD significantly increased the red/
green fluorescence intensity of the mitochondria to 86 ± 13%, 
illustrating that Wnt1 can significantly improve mitochondrial 
permeability transition pore membrane potential (Figs. 6A and 
B). Yet, inhibition of Wnt1 activity with Wnt1Ab (1 μg/ml) 
or with application of DKK-1 (0.5 μg/ml) during combined 
Wnt1 (100 ng/ml) application lead to significant mitochondrial 
depolarization during OGD, suggesting that the presence of 
Wnt1 activity is important for the control of mitochondrial 
permeability during OGD. Furthermore, inhibition of Akt1 
activity by SH-5 (20 μM) during Wnt1 (100 ng/ml) applica-
tion  also  resulted  in  the  loss  of  mitochondrial  permeability   
during OGD, demonstrating that Wnt1 uses Akt1 activation 
for  the  preservation  of  mitochondrial  membrane  function   
(Fig. 6A and B).
Figure 4. Wnt1 relies upon the pI 3-K pathway and Akt1 to provide 
neuronal protection. In A, primary neuronal protein extracts (50 μ/lane) 
were immunoblotted with anti-phosphorylated-Akt1 (p-Akt1, ser473) or 
anti-total Akt1 at 6 hours following OGD. Application of Wnt1 (100 ng/
ml) in untreated wildtype neurons or in the presence of OGD signifi-
cantly elevated p-Akt1 expression to a greater extent than OGD alone. 
This increased expression of p-Akt1 by Wnt1 was blocked by the pI 3-K 
inhibitor wortmannin (0.5 μM) and by the specific Akt1 inhibitor sh-5 
(20 μM). Total Akt1 is not altered (*p < 0.01, vs. OGD; †p < 0.01 vs. Wnt1/
OGD). each data point represents the mean and seM from six experi-
ments. In B, primary neurons treated with Wnt1 (100 ng/ml) increased 
neuronal survival assessed by trypan blue staining 24 hours after OGD. 
Yet, application of wortmannin (0.5 μM) or sh-5 (20 μM) at concentra-
tions that block activation of Akt1 activation significantly reduced 
protection by Wnt1 24 hours after OGD (*p < 0.01, vs. OGD; †p < 0.01 
vs. Wnt1/OGD). each data point represents the mean and seM from six 
experiments.158  Oxidative Medicine and Cellular Longevity  Volume 3 Issue 2
OGD within 3 hours also produced a significant release of 
cytochrome c from the mitochondria to a 2.1 ± 0.1-fold increase 
when compared to untreated control mitochondria using west-
ern analysis (Fig. 6C and D). Wnt1 (100 ng/ml) during OGD 
prevented cytochrome c release to a similar degree that occurs 
with untreated control neuronal mitochondria (Fig. 6C and D). 
However, inhibition of Wnt1 activity with Wnt1Ab (1 μg/ml) 
or with application of DKK-1 (0.5 μg/ml) as well as the inhibi-
tion of Akt1 activity by SH-5 (20 μM) during Wnt1 (100 ng/ml) 
administration  prevent  Wnt1  from  controlling  the  release  of 
cytochrome c during OGD, supporting the premise that Wnt1 
signaling in conjunction with Akt1 is required for preventing the 
release of cytochrome c from mitochondria in neurons during 
OGD exposure (Fig. 6C and D).
Transient  cerebral  ischemia  suppresses 
endogenous  Wnt1  cortical  expression  but 
exogenous Wnt1 reduces cerebral infarction. 
Similar  to  our  studies  that  investigated  the 
effects of OGD on Wnt1 endogenous expres-
sion in primary neurons, we examined whether 
cerebral  ischemia  in  a  transient  MCAO  rat 
model alters Wnt1 expression the cerebral cor-
tex. To investigate the expression of Wnt1 in 
the cerebral cortex, focal cerebral ischemia was 
induced by insertion of a monofilament thread 
(4-0) into internal carotid artery and block-
ade of the origin of MCA. Reperfusion was 
performed following 90 minutes ischemia by 
withdrawal of the thread. As shown in Figure 
7A and similar to our in vitro studies, tran-
sient cerebral ischemia initially increased the 
expression of Wnt1 at 1 and 6 hours following 
MCAO when compared to control. However, 
a significant decrease in Wnt1 expression was 
lost in the cortex at 24 hours following focal 
MCAO.  Quantitative  results  demonstrate 
that Wnt1 expression is significantly increased 
approximately 1.8-fold at 1 hour and 2.0-fold 
at 6 hours in the cortex following MCAO, but 
is significantly decreased to approximately 1.0-
fold at 24 hours after MCAO (Fig. 7A). Wnt1 
expression on the contralateral non-infarction 
hemisphere was not altered from control, illus-
trating that the generation of cerebral ischemia 
directly led to changes in endogenous Wnt1 
expression (Fig. 7A).
Loss of Wnt1 expression following MCAO 
may be associated with hemisphere infarction. 
Following  focal  MCAO  and  reperfusion  90 
minutes later, we assessed cerebral infarct size 
with 2,3,5-triphenytetrazolium (TTC) stain-
ing 24 hours following MCAO and reperfu-
sion. In Figure 7B and 7C, MCAO resulted 
in an approximate 65% infarction of the hemi-
sphere over the same period that endogenous 
Wnt1 expression is lost as shown in Fig. 7A. 
However, treatment with recombinant Wnt1 protein (24 μg/kg) 
administered into internal carotid artery through the external 
carotid artery prior to the onset of MCAO and once again during 
the onset of reperfusion markedly reduced cerebral infarction to 
a level of 30 ± 8% (Fig. 7B and C).
Wnt1 is necessary for reduction in cerebral infarction fol-
lowing transient cerebral MCAO and preserves neurological 
recovery. Given that exogenous Wnt1 application prior to cere-
bral MCAO infarction and reperfusion resulted in a significant 
reduction in cerebral infarct size per our studies in Figure 7B 
and C, we next evaluated whether blockade of Wnt1 and its 
signaling  pathways  could  alter  cerebral  protection  by  Wnt1. 
In  Figure  8A,  representative  serial  cortical  images  reveal  sig-
nificant  infarction  in  animals  treated  only  with  vehicle. 
Figure 5. Wnt1 uses Akt1 to block apoptotic membrane ps exposure and genomic DNA 
degradation during OGD. In A, representative images illustrate that recombinant human 
Wnt1 protein (100 ng/ml) significantly blocks neuronal genomic DNA degradation assessed 
by TUNeL and membrane ps externalization assessed by annexin V phycoerythrin (green 
fluorescence) 24 hours following OGD. In contrast, inhibition of Wnt1 (100 ng/ml) signaling 
with Wnt1Ab (1 μg/ml) or with application of DKK-1 (0.5 μg/ml) or inhibition of Akt1 with sh-5 
(20 μM) during Wnt1 application leads to the loss of Wnt1 protection. In B, quantification of 
data illustrates that DNA fragmentation and membrane ps externalization were significantly 
increased 24 hours following OGD when compared to untreated neuronal control cultures 
during Wnt1 (100 ng/ml) application with Wnt1Ab (1 μg/ml), DKK-1 (0.5 μg/ml), or sh-5  
(20 μM). each data point represents the mean and seM from six experiments.www.landesbioscience.com  Oxidative Medicine and Cellular Longevity  159
Compilation of the total hemisphere infarction resulted in an 
approximate 50% infarction shown in Figure 8B. In contrast, 
treatment with recombinant Wnt1 protein (24 μg/kg) prior to 
the onset of MCAO and once again during the onset of reperfu-
sion resulted in significant cerebral hemisphere protection with an 
infarct size of approximate 28% (Fig. 8A and B). Furthermore, 
treatment with Wnt1Ab (60 μg/kg) or DKK-1 (30 μg/kg) prior 
to the onset of MCAO and once again during the onset of rep-
erfusion  significantly  increased  infarct  size  to  approximately 
62% for each agent, illustrating that loss of Wnt1 activity or the 
induction of its downstream signal transduction pathways leads 
to marked cerebral injury following transient MCAO. In addi-
tion, cerebral infarction with these agents was worse than during 
vehicle administration alone, suggesting that an endogenous level 
of Wnt1 in the cerebral hemisphere may be required for endog-
enous protection against cerebral injury (Fig. 8A and B).
More  importantly,  cerebral  protection  by  Wnt1  appears 
not  only  to  be  tied  to  reduction  in  cerebral  infarct  size  fol-
lowing  MCAO,  but  also  is  associated  with  improved  neu-
rological  function.  In  Figure  8C,  vehicle  administration 
resulted in significant neurological score deficit of 2.3 ± 2%. Yet, 
Wnt1 (24 μg/kg) prior to the onset of MCAO and once again 
during the onset of reperfusion reduced the neurological deficit in 
animals to 1.3 ± 0.2%. In contrast, treatment with Wnt1Ab (60 
μg/kg) or DKK-1 (30 μg/kg) prior to the onset of MCAO and 
once again during the onset of reperfusion not only significantly 
increased the neurological deficit score but to a greater degree 
than vehicle treated animals, further supporting that blockade of 
Wnt1 pathways prevents the ability of endogenous Wnt1 to offer 
cerebral protection during MCAO injury (Fig. 8B and C).
Discussion
Wnt proteins play a significant role in several biological func-
tions that involve embryonic cell proliferation, cellular differ-
entiation, and cell survival.4,7,31,47-57 Furthermore, Wnt signaling 
that involves β-catenin can promote renal cell survival during 
metabolic stress56 and may be involved in processes of transitional 
development such as muscle-to-fat cell conversion.55 Yet, the role 
of Wnt during cell injury, oxidative stress, and potential for drug 
Figure 6. Wnt1 inhibits mitochondrial depolarization and prevents the release of cytochrome c during OGD. In A, OGD leads to a significant decrease 
in the red/green fluorescence intensity ratio of mitochondria using the cationic membrane potential indicator JC-1 within 3 hours when compared 
with untreated control neurons, demonstrating that OGD leads to mitochondrial membrane depolarization. Application of Wnt1 (100 ng/ml) during 
OGD significantly increased the red/green fluorescence intensity of mitochondria in neurons, illustrating that mitochondrial membrane potential was 
restored by Wnt1. In contrast, inhibition of Wnt1 (100 ng/ml) signaling with Wnt1Ab (1 μg/ml) or with application of DKK-1 (0.5 μg/ml) or inhibition of 
Akt1 with sh-5 (20 μM) during Wnt1 application and OGD resulted in mitochondrial depolarization similar to OGD exposure alone. In B, the relative 
ratio of red/green fluorescent intensity of mitochondrial staining in untreated control neurons, in neurons exposed to OGD, during Wnt1 (100 ng/ml)/
OGD application alone or during Wnt1 (100 ng/ml)/OGD with Wnt1Ab (1 μg/ml), DKK-1 (0.5 μg/ml), or sh-5 (20 μM) was measured in six independent 
experiments with analysis performed using the public domain NIh Image program (http://rsb.info.nih.gov/nih-image) (Wnt1/OGD vs. OGD, *p < 0.01; 
Wnt1/OGD with Wnt1Ab, DKK-1, or sh-5 vs. Wnt1/OGD, †p < 0.01). In C and D, equal amounts of mitochondrial (mito) or cytosol (cyto) protein extracts 
(50 μg/lane) were immunoblotted demonstrating that Wnt1 (100 ng/ml) significantly prevented cytochrome c release from mitochondria within 3 
hours after OGD but Wnt1Ab (1 μg/ml), DKK-1 (0.5 μg/ml), or sh-5 (20 μM) during Wnt1/OGD application prevented Wnt1 from maintaining cyto-
chrome c in the mitochondria (Wnt1/OGD vs. OGD, *p < 0.01; Wnt1/OGD with Wnt1Ab, DKK-1, or sh-5 vs. Wnt1/OGD, †p < 0.01).160  Oxidative Medicine and Cellular Longevity  Volume 3 Issue 2
Figure 7. Transient cerebral ischemia blocks endogenous Wnt1 cortical 
expression but exogenous Wnt1 is protective against cerebral ischemia. 
In A and B, focal cerebral ischemia was induced by insertion of a mono-
filament thread (4-0) into the internal carotid artery and blockade of 
the origin of MCA. Reperfusion was performed following 90 minutes 
ischemia by withdrawal of the thread. For A, cortical protein extracts 
(50 μg/lane) were immunoblotted with anti-Wnt1 (Wnt1) at 1, 6 and 
24 hours following OGD exposure. similar to the effects upon Wnt1 
expression with OGD in neuronal cultures, Wnt1 expression is initially 
elevated at 1 hour and 6 hours, but then progressively and significantly 
is reduced at 24 hours following OGD exposure (*p < 0.01 vs. control). 
Wnt1 expression on the contralateral non-infarction hemisphere was 
not altered from control, illustrating that the generation of cerebral 
ischemia directly led to changes in endogenous Wnt1 expression.  
In B, Wnt1 protein (24 μg/kg) was injected into the internal carotid ar-
tery through the external carotid artery at 30 minutes prior to the onset 
of MCAO and at the onset of reperfusion. Animals were euthanized 
24 hours following ischemia and the infarct size was determined by 
2,3,5-triphenytetrazolium (TTC) staining. Representative images show 
that the infarct size (white in color) was significantly reduced by treat-
ment with Wnt1 protein. In C, quantitative results demonstrate that 
infarct size was significantly decreased by Wnt1 (24 μg/kg) treatment 
following reperfusion after cerebral ischemia. The total infarct size was 
expressed as a percentage of the contralateral hemisphere (*p < 0.05 vs. 
vehicle). In all cases, each data point represents the mean and seM from 
six experiments.
Figure 8. Wnt1 signaling is required for reduction in cerebral infarction 
following transient cerebral MCAO and maintains neurological recov-
ery. In A, B and C, focal cerebral ischemia was induced by insertion of a 
monofilament thread (4-0) into the internal carotid artery and blockade 
of the origin of MCA. Reperfusion was performed following 90 minutes 
ischemia by withdrawal of the thread. In A, Wnt1 protein (24 μg/kg), 
Wnt1Ab (60 μg/kg), or DKK-1 (30 μg/kg) was injected into the internal 
carotid artery through the external carotid artery at 30 min prior to the 
onset of MCAO and at the onset of reperfusion. Animals were eutha-
nized 24 hours following ischemia and infarct size was determined 
by 2,3,5-triphenytetrazolium (TTC) staining. Representative images 
illustrate that infarct size (white in color) was significantly reduced by 
treatment with Wnt1 protein. In contrast, infarct size was markedly 
increased by treatment with Wnt1Ab or DKK-1 during MCAO. In B, quan-
titative results demonstrate that infarct size was significantly decreased 
by Wnt1 (24 μg/kg) treatment following reperfusion after MCAO. how-
ever, infarct size was substantially increased with Wnt1Ab (60 μg/kg) or 
DKK-1 (30 μg/kg) administration during MCAO. The total infarct size was 
expressed as a percentage of the contralateral hemisphere (*p < 0.05 
vs. vehicle). In C, the neurological deficit score was assessed in animals 
24 hours following MCAO and reperfusion of a 90 minute period. Wnt1 
(24 μg/kg) significantly lowered the neurological deficit score when 
compared to vehicle only treated animals. In contrast, Wnt1Ab  
(60 μg/kg) or DKK-1 (30 μg/kg) significantly increased the neurological 
deficit score (*p < 0.05 vs. vehicle). In all cases, each data point repre-
sents the mean and seM from six experiments.www.landesbioscience.com  Oxidative Medicine and Cellular Longevity  161
platform development require further investigation.58 Wnt sig-
naling has recently been reported to be downregulated in bone 
tissue during ethanol-induced oxidative stress,59 in endothelial 
cells during elevated glucose19 and in neurons during β-amyloid 
toxicity.27 We now show that Wnt1 expression is significantly 
diminished during oxidative stress in neurons in vitro and in 
vivo. Initially, Wnt1 expression is upregulated at 1 hour and 6 
hours following OGD in primary hippocampal neurons and 
in the cerebral cortex following MCAO with reperfusion, sug-
gesting that an endogenous cellular response occurs to increase 
Wnt1 expression during an oxidative stress insult. However, 
over a 24 hour course in both primary hippocampal neurons 
and in the cerebral cortex, endogenous Wnt1 expression is sig-
nificantly lost that correlates with progressive neuronal injury.
Interestingly, we demonstrate that if expression of Wnt1 is 
maintained such as with transient overexpression of Wnt1 in 
primary neurons or with administration of the recombinant 
Wnt1 protein, both primary hippocampal neurons and cerebral 
cortical tissue are protected from oxidative stress. Prior stud-
ies  have  shown  that  co-culture  of  fibroblasts  overexpressing 
Wnt1 can protect lymphoid cells from apoptosis60 and loss of 
β-catenin can increase infarct size during cerebral ischemia.61 
In addition, overexpression of Wnt1 blocks β-amyloid toxicity 
in neuronal cells27 and administration of recombinant Wnt1 
protects cells against apoptotic demise during elevated glucose 
in endothelial cells.19 We also demonstrate that Wnt1 has the 
ability to block both early apoptotic early PS externalization 
in neurons as well as subsequent genomic DNA degradation. 
This capacity of Wnt1 may be crucial for the therapeutic target-
ing of Wnt signaling for numerous disorders. Externalization of 
membrane PS residues during apoptosis can occur much earlier 
than nuclear DNA degradation and promote hypercoagulable 
states21,62 that lead to cardiovascular injury. PS exposure also 
can alert inflammatory cells to quickly phagocytize and elimi-
nate injured cells with PS markings, potentially also removing 
functional cells and promoting further disability.36,43,63-67
Our in vivo and in vitro studies suggest that neuronal protec-
tion by Wnt1 is specific for Wnt1 signaling. With the MCAO 
experimental model, we initially observed that Wnt1 expression 
on the contralateral non-infarction hemisphere was not altered 
from control, but the ipsilateral ischemic hemisphere suffered 
from eventual loss of Wnt1 expression. This observation suggests 
that only cortical tissue subjected to oxidant stress is susceptible 
to injury as a result of the loss of endogenous Wnt1 expres-
sion. Our neuronal cell cultures studies also point to a course 
of cell demise over 24 hours following OGD that directly cor-
relates with the loss of Wnt1 expression. Our subsequent studies 
employed the blockade of Wnt1 signaling with a Wnt1Ab or the 
antagonism of the Wnt/β-catenin pathway with DKK-1,7,32 an 
agent also considered for disorders with excessive Wnt activ-
ity,68 to illustrate that in primary neurons Wnt1Ab or DKK-1 
can abrogate protection by Wnt1 during OGD, demonstrating 
that Wnt1 is necessary, at least as one potential component, to 
prevent cell injury and apoptotic PS exposure and DNA deg-
radation. Furthermore, in the MCAO animal model, Wnt1Ab 
or DKK-1 worsened infarct size and increased the neurological 
deficit score, illustrating that endogenous Wnt1 in the brain 
offers significant protection against oxidative stress injury and 
functional recovery.
Neuronal protection by Wnt1 also relies upon the activa-
tion of Akt1, a pathway with increasing prominence for con-
sideration  in  Wnt  signaling.7,29,30,32,69  Several  studies  have 
documented that Wnt can rely upon Akt activation to support 
cell survival.27,52,56,70-72 In addition, Akt is a primary pathway 
to promote cell survival and growth such as during inflam-
mation,73,74  cardiomyocyte  hypertrophy,75  ischemic-precondi-
tioning,76  hypoxia,36 amyloid  toxicity,27,37,77-79  excitotoxicity,80 
vascular disease81 and oxidative stress.41-43 We show that Wnt1 
in primary hippocampal neurons maintains the phosphoryla-
tion and activation of Akt1 that would otherwise be lost dur-
ing  OGD  exposure.  More  importantly,  our  work  illustrates 
that inhibition of the PI 3-K pathway or specific inhibition of 
Akt1 activity leads to the loss of protection by Wnt1 against cell 
injury, membrane PS exposure, and DNA degradation during 
oxidative stress with OGD, demonstrating that Akt1 is a vital 
downstream pathway for Wnt1 neuronal protection.
In addition to reliance upon Akt1, we show that Wnt1 also 
regulates  mitochondrial  membrane  permeability  and  cyto-
chrome  c  release  in  conjunction  with  Akt1.  Mitochondrial 
membrane permeability plays a significant role during cell sur-
vival and the initiation of the apoptotic cascade,41,80,82 especially 
during oxidative stress.20,28,83-86 In addition, Wnt signaling path-
ways have been tied to apoptotic mitochondrial signaling.27,72 
Given that Akt1 maintains mitochondrial membrane potential, 
prevent cytochrome c release87-89 and block caspase activity,36,87,89 
the  ability  of  Wnt1  to  oversee  mitochondrial  permeability 
appears to be a direct extension of the control of Akt1. Our 
studies illustrate that Wnt1 is necessary to prevent mitochon-
drial membrane permeability and the release of cytochrome c 
during OGD, since blockade of Wnt1 signaling with Wnt1Ab 
or DKK-1 removes the ability of Wnt1 to perform this function. 
Furthermore, Wnt1 does employ Akt1 to modulate mitochon-
drial membrane permeability since specific inhibition of Akt1 
with SH-5 prevents maintenance of mitochondrial membrane 
function and cytochrome c release during OGD.
Wnt signaling is a vital component for the modulation of cell 
and tissue growth in the nervous system, but the role of Wnt1 
as a cytoprotectant against apoptotic neurodegeneration during 
oxidative stress is only recently being elucidated. Our studies 
provide further understanding of Wnt signaling in regards to 
Wnt1 during oxidative stress. Our work illustrates that Wnt1 
not  only  enhances  primary  neuronal  cell  survival  in  both 
in vitro and in vivo experimental models of oxidative stress, 
but also prevents the onset of early and late apoptotic injury   
programs of PS membrane externalization and nuclear DNA 
degradation during OGD. Wnt1 is a critical component against 
apoptotic neurodegeneration since blockade of Wnt1 signaling 
leads to the abrogation of Wnt1 cytoprotection. Furthermore, 
the protection offered to primary neurons by Wnt1 translates 
into improved functional recovery, highlighting the potential of 
Wnt1 pathways for clinical utility. Ultimately, neuroprotection 
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the apoptotic loss in mitochondrial permeability and the release 
of cytochrome c. Our work presents new avenues for Wnt1 and 
its downstream modulation of Akt1 and mitochondrial mem-
brane permeability for the consideration of novel therapies for a 
multitude of disorders tied to oxidative stress.
Materials and Methods
Primary hippocampal neuronal cultures. Briefly per our prior 
protocols,90,91 the hippocampi were obtained from E-19 Sprague-
Dawley rat pups and incubated in Hanks’ balanced salt solution 
(HBBS) supplemented with 1 mM sodium pyruvate and 10 mM 
HEPES buffer solution (Invitrogen, Carlsbad, CA). The neurons 
were isolated by trituration with 10 repetitions and then centri-
fuged for 2 minutes at 200 g. The cells were washed in growth 
medium (Leibovitz’s L-15 medium, Invitrogen, Carlsbad, CA) 
containing 6% sterile rat serum (ICN, Aurora, OH), 150 mM 
NaHCO3, 2.25 mg/ml of transferrin, 2.5 μg/ml of insulin,   
10  nM  progesterone,  90  μM  putrescine,  15  nM  selenium,   
35 mM glucose, 1 mM L-glutamine, penicillin and streptomy-
cin (50 μg/ml), and vitamins. The dissociated neurons were 
plated at a density of ~1.5 x103 cells/mm2 in 35 mm polylysine/
laminin-coated plates and were maintained in growth medium 
at 37°C in a humidified atmosphere of 5% CO2 and 95% room 
air for 10–14 days. All animal experimentation was conducted 
in accord with accepted standards of humane animal care and 
NIH guidelines.
Experimental  treatments.  Oxygen-glucose  deprivation 
(OGD) in microglia was performed by replacing the media with 
glucose-free HBSS containing 116 mmol/l NaCl, 5.4 mmol/l 
KCl, 0.8 mmol/l MgSO4, 1 mmol/l NaH2PO4, 0.9 mmol/l CaCl2 
and 10 mg/l phenol red (pH 7.4) and cultures were maintained in 
an anoxic environment (95% N2 and 5% CO2) at 37°C per the 
experimental paradigm. For treatments applied prior to OGD, 
human recombinant Wnt1 protein (R&D Systems, Minneapolis, 
MN) or mouse monoclonal anti body against Wnt1 (Wnt1Ab) 
(R&D  Systems,  Minneapolis,  MN),  the  phosphatidylinositol 
3-kinase (PI-3 K) inhibitor wortmannin (Calbiochem, La Jolla, 
CA),  the  recombinant  Wnt  antagonist  dickkopf  related  pro-
tein 1 (DKK-1, 0.5 μg/ml, R&D Systems, Minneapolis, MN), 
or  D-3-deoxy-2-O-methyl-myo  inositol  1-(R)-2-methoxy-3-
(octadecyloxy) propyl hydrogen phosphate (SH-5) (Alexis, San 
Diego, CA) were continuous.
Assessment of cell survival. Cell injury was determined by 
bright field microscopy using a 0.4% trypan blue dye exclusion 
method 24 hours following treatment with OGD per our pre-
vious protocols.42,43,63,92 The mean survival was determined by 
counting  eight  randomly  selected  non-overlapping  fields  with 
each containing approximately 10–20 cells (viable + non-viable). 
Each experiment was replicated six times independently with dif-
ferent cultures.
Assessment  of  DNA  fragmentation.  Genomic  DNA  frag-
mentation  was  determined  by  the  terminal  deoxynucleoti-
dyl  transferase  nick  end  labeling  (TUNEL)  assay.36,42  Briefly, 
microglial cells were fixed in 4% paraformaldehyde/0.2% picric 
acid/0.05% glutaraldehyde and the 3'-hydroxy ends of cut DNA 
were labeled with biotinylated dUTP using the enzyme terminal 
deoxytransferase (Promega, Madison, WI) followed by strepta-
vidin-peroxidase  and  visualized  with  3,3'-diaminobenzidine 
(Vector Laboratories, Burlingame, CA). 
Assessment  of  membrane  phosphatidylserine  (PS)  resi-
due  externalization.  Phosphatidylserine  (PS)  exposure  was 
assessed through the established use of annexin V. Per our 
prior protocols41,42 a 30 μg/ml stock solution of annexin V con-
jugated to phycoerythrin (PE) (R&D Systems, Minneapolis, 
MN) was diluted to 3 μg/ml in warmed calcium containing 
binding buffer (10 mmol/l Hepes, pH 7.5, 150 mmol/l NaCl, 
5 mmol/l KCl, 1 mmol/l MgCl2, 1.8 mmol/l CaCl2). Plates 
were incubated with 500 μl of diluted annexin V for 10 min-
utes. Images were acquired with “blinded” assessment with a 
Leitz DMIRB microscope (Leica, McHenry, IL) and a Fuji/
Nikon Super CCD (6.1 megapixels) using transmitted light 
and fluorescent single excitation light at 490 nm and detected 
emission at 585 nm.
Transient transfection of Wnt1 cDNA construct in primary 
neurons. Overexpression of Wnt1 was generated by transfecting 
cells with Wnt1 cDNA construct under the control of a CMV 
promoter with HA-tagged Wnt1 cDNA (6.75 kb) inserted into 
the Xba I site of pUSEamp (+) vector (Upstate Biotechnology, 
Lake Placid, NY). Cells were seeded into 35 mm dishes at a con-
centration of 1-1.5 x 105 and transfected with 1 μg cDNA by using 
lipofection  with  Lipofectamine  reagent  (Invitrogen,  Carlsbad, 
CA) according to the instructions of the manufacturer.
Expression of Wnt1, phosphorylated Akt1, and total Akt1. 
Cells were homogenized and each sample (50 μg/lane) was sub-
jected to SDS-polyacrylamide gel electrophoresis (12.5% Wnt1, 
7.5% Akt1). After transfer, the membranes were incubated with a 
rabbit polyclonal antibody against Wnt1 (1:1000, R&D Systems, 
Minneapolis, MN), a rabbit polyclonal antibody against phos-
pho-Akt1  (Ser473,  1:1000,  Cell  Signaling,  Beverly,  MA),  or  a 
rabbit antibody against total Akt1. Following washing, the mem-
branes were incubated with a horseradish peroxidase (HRP) con-
jugated secondary antibody goat anti-rabbit IgG (1:2000, Zymed 
Laboratories, Carlsbad, CA). The antibody-reactive bands were 
revealed by chemiluminescence (Amersham Pharmacia Biotech, 
Piscataway, NJ) and band density was performed using the pub-
lic domain NIH Image program (developed at the US National 
Institutes of Health and available at http://rsb.info.nih.gov/nih-
image/).
Assessment  of  mitochondrial  membrane  potential.  The 
fluorescent probe JC-1 (Molecular Probes, Eugene, OR), a cat-
ionic membrane potential indicator, was used to assess the mito-
chondrial membrane potential. Microglia in 35 mm dishes were 
incubated with 2 μg/ml JC-1 in growth medium at 37°C for   
30 min. The cultures were washed three times using fresh growth 
medium. Mitochondria were then analyzed immediately under 
a Leitz DMIRB microscope (Leica, McHenry, IL, USA) with 
a dual emission fluorescence filter with 515-545 nm for green   
fluorescence and emission at 585-615 nm for red fluorescence.42
Preparation of mitochondria for the analysis of cytochrome 
c release. After washing once with ice-cold PBS, cells were har-
vested,  homogenized,  and  the  supernatants  were  centrifuged www.landesbioscience.com  Oxidative Medicine and Cellular Longevity  163
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at 10,000 g for 15 minutes at 4°C. The resulting pellet was re-
suspended in buffer A (20 mM HEPES, pH 7.5, 10 mM KCl,   
1.5 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 1 mM dithio-
threitol, 0.1 phenylmethylsulfonylfluoride) containing 250 mM 
sucrose and used as the mitochondrial fraction. The supernatant 
was subjected to ultracentrifugation at 50,000 g for 1 hour at 
4°C with the resultant supernatant used as the cytosolic frac-
tion.42. Western blot detection for cytochrome c was performed 
by using a rabbit polyclonal antibody against cytochrome c 
(1:1000, Cell Signaling, Beverly, MA).
Reversible  middle  cerebral  artery  occlusion  (MCAO). 
Focal cerebral ischemia was induced by occlusion of the ori-
gin  of  middle  cerebral  artery  (MCA)  through  insertion  of 
intraluminal suture into the external carotid artery and then 
into the internal carotid artery to pass the origin of MCA.93,94 
Briefly,  male  Sprague-Dawley  rats  (280~300  g)  were  anes-
thetized  with  chloral  hydrate  (350  mg/kg,  intraperitoneal).   
A 2 cm midline incision was made in the neck to expose the 
left  common  carotid,  external  carotid,  and  internal  carotid 
arteries.  Dissection  of  the  arteries  was  performed  to  free 
them from surrounding nerves and tissues. A monofilament 
thread (4-0 with coating at the tip, Doccol, Redlands, CA) 
was inserted from the external carotid artery into the lumen of 
internal carotid artery and advanced into the internal carotid 
artery for 22 mm (from the bifurcation of the common carotid 
artery).  The  suture  surrounding  the  external  carotid  artery 
to prevent bleeding was tightened and secured. Reperfusion 
was performed by withdrawal of the monofilament suture and 
closure  of  the  external  carotid  artery.  For  treatment  proto-
cols, Wnt1 protein (24 μg/kg) (R&D System, Minneapolis, 
MN), Wnt1 antibody (15 μg/ml) (R&D System, Minneapolis, 
MN), or Wnt1 antagonist DKK-1 (24 μg/kg) (R&D System, 
Minneapolis, MN) were injected into internal carotid artery 
(ICA) through external carotid artery (ECA) at 30 minutes 
prior to MCAO and at the onset of reperfusion. Rectal temper-
ature was maintained at 36.5 to 37.5°C throughout the experi-
ment with a thermal blanket. All animal experimentation was 
conducted in accord with accepted standards of humane animal   
care and NIH guidelines.
MCAO infarct size determination. Animals were euthanized 
24 hours following ischemia by decapitation and the brains were 
sliced into 3 mm coronal sections. The slices were incubated 
in 2% 2,3,5-triphenytetrazolium (TTC) solution for 30 min-
utes at 30°C and then were fixed in 4% paraformaldehyde. Each 
slice was scanned and the infarct area and the area of the con-
tralateral hemisphere were performed using the public domain 
NIH Image program (developed at the US National Institutes 
of Health and available at http://rsb.info.nih.gov/nih-image/). 
The total infarct size was expressed as percentage of contralateral 
hemisphere.
Post MCAO animal neurological evaluation. Neurological 
deficit scores following MCAO in rats were determined by the 
following  modified  criteria95,96:  no  apparent  deficit  observed, 
deficit score = 0; with the animal suspended, only contralat-
eral limb flexion observed, deficit score = 1; with the animal 
placed on a grille and gently pulled by the tail, the animal shows 
decreased grip in the contralateral forelimb, deficit score = 2; 
with the animal held by the tail and allowed to move freely 
showing cycling towards the contralateral side, deficit score = 3; 
and with the animal displaying severe paralysis without move-
ment, deficit score = 4.
Statistical  analysis.  For  each  experiment,  the  mean  and 
standard error were determined. Statistical differences between 
groups were assessed by means of analysis of variance (ANOVA) 
from six replicate experiments with the post-hoc Dunnett’s test. 
Statistical significance was considered at p < 0.05.
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